… Erenumab was … and safety of monthly erenumab (70 mg or 140 mg) versus placebo in the
subgroup of patients who had previously failed preventive treatment(s) (≥ 1, ≥ 2 prior failed …

… who have previously failed treatment with other preventive … safety, and tolerability of
erenumab in the subgroup of patients in STRIVE who had failed migraine preventive treatment…

… -term effects of monthly erenumab 140 mg in individuals with EM in whom 2–4 migraine
preventives had failed, ~70% of≥50% responders in the erenumab treatment arm at the onset …

… preventive treatment(s)? This study provides evidence that efficacy was sustained with
erenumab treatment in patients with CM in whom prior preventive treatments had failed, and that …

… the safety and efficacy of erenumab in patients with prior preventive treatment failures. We
… The 140 mg monthly dose of erenumab had a numerical advantage over the 70 mg monthly …

… assessed the efficacy and safety of erenumab 70 mg for the … safety of erenumab 70 mg
treatment in the subgroups of Japanese patients with/without prior preventive treatment failure…

… The tolerability and safety profiles of erenumab and placebo were similar. The most … of
subgroups of patients with previous treatment failure in earlier migraine trials with erenumab. …

… or erenumab in the DBTP after receiving erenumab in the OLEP. Considering a recent
update to the erenumab … (FDA) to change the safety label to indicate possible erenumab-induced …

… or deemed not suitable for another preventive treatment such as propranolol or metoprolol…
failed or deemed not suitable for valproate or divalproex. Treatment failure (efficacy and safety…

… , we present the efficacy and safety of erenumab 140 mg at the completion of … erenumab
in patients with difficult-to-treat EM in whom 2–4 prior migraine preventive treatments had failed …